Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,282.40
(
0.00%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
109.86
(
1.60%
)
Bitcoin
68,005.96
(
0.25%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: King Stuki post# 2682

Wednesday, 06/30/2004 2:30:21 PM

Wednesday, June 30, 2004 2:30:21 PM

Post# of 257269
>> Was GENR driving too hard a bargain or is there some other factor working here? My guess is GENR and Merck talked. <<

It’s close to 100% that the two companies talked, at least casually.

GENR may be overplaying its cards, thinking it has a royal straight flush when in reality it has a full house. Based on GENR’s ASCO press release, Levitt may still believe –or pretend to believe-- that Squalamine has a great future in cancer. If so, this would present an obstacle to bringing a licensing deal to fruition.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today